--News Direct--
Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company has made great progress towards commercialisation in a Phase 1C study of its topical Pan LOX inhibitor, achieving a well-tolerated safety profile and a marked change in scar composition. Importantly, the study’s results mark the first-ever proof that LOX inhibition reduces skin collagen, having achieved a 30% reduction in the scar’s collagen content.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/pharmaxis-extends-scarring-collaboration-after-encouraging-results-117575065
